HAYWARD, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and CEO, will present at the BIO Investor Forum in San Francisco at the Palace Hotel on Thursday, October 11, 2007 at 11:30 a.m. Pacific Time. A live webcast of the presentation can be accessed through http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KOSN&item_id=16576 63.
Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentation will be available for two weeks.
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple
pathways involved in cancer cell growth and survival. Tanespimycin
(KOS-953) is being tested in combination with bortezomib (Velcade(R)) in
patients with multiple myeloma in a registration program called TIME.
Tanespimycin is also being studied in HER2-positive metastatic breast
cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy
in metastatic melanoma. Intravenous and oral formulations of Kosan's
|SOURCE Kosan Biosciences Incorporated|
Copyright©2007 PR Newswire.
All rights reserved